Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04661657 · ClinicalTrials.gov registry record
COvid-19 LongitUdinal Multiethnic BioImaging Assessment of CARDiovascular Sequelae Registry
A clinical trial, sponsored by Columbia University.
- Completed
- Registry status
- 52
- Enrollment target
NCT04661657: Completed study, sponsored by Columbia University.
NCT04661657 is a clinical trial that has completed, run by Columbia University. The registered enrollment target is 52 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04661657 has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
Study Summary
COLUMBIA CARDS is a pilot study to understand how COVID-19 affects the heart. It is known that COVID-19 can affect the heart in different ways. COLUMBIA CARDS is studying why some COVID-19 survivors develop clinical conditions such as heart inflammation, fluid buildup, blood clots, and other cardiac problems during or after their COVID-19 illness, and why other ones do not. In this study, we will use cardiovascular magnetic resonance (CMR) and transthoracic echocardiography (TTE) to better understand the impact of COVID-19 on the heart.
Primary Outcome
Percentage of myocardium demonstrating late gadolinium enhancement by cardiac magnetic resonance (CMR) imaging, determined using Circle cvi42 software.
Interventions
- OTHER Transthoracic echocardiogram (TTE)
- OTHER Cardiovascular Magnetic Resonance (CMR) Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2020-12-28 |
| Est. Completion | 2022-01-22 |
What the finished NCT04661657 record still lists
NCT04661657 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 52 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Transthoracic echocardiogram (TTE) is the first listed.
NCT04661657 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04661657 about?
NCT04661657 is a clinical study titled "COvid-19 LongitUdinal Multiethnic BioImaging Assessment of CARDiovascular Sequelae Registry". COLUMBIA CARDS is a pilot study to understand how COVID-19 affects the heart. It is known that COVID-19 can affect the heart in different ways. COLUMBIA CARDS is studying why some COVID-19 survivors develop clinical conditions such as heart inflammation, fluid buildup, blood clots, and other cardiac...
What is the current status of trial NCT04661657?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2020-12-28. Estimated completion is 2022-01-22.
What interventions are being tested in trial NCT04661657?
The interventions under investigation include: Transthoracic echocardiogram (TTE) (OTHER), Cardiovascular Magnetic Resonance (CMR) Imaging (OTHER).
Who is sponsoring clinical trial NCT04661657?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI